Drug Search Results
More Filters [+]

Revexepride

Alternative Names: revexepride, ssp-002358, ssp002358, ssp 002358, spd-557, spd557, spd 557
Latest Update: 2021-06-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT4 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Revexepride

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Gastroesophageal Reflux|Esophagitis, Peptic|Heartburn|Bile Reflux

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SPD557-206

P2

Completed

Bile Reflux|Gastroesophageal Reflux|Heartburn

2013-05-14

SPD557-206

P2

Completed

Gastroesophageal Reflux|Esophagitis, Peptic

2013-05-14

SPD557-107

P1

Completed

Healthy Volunteers

2013-04-12

SPD557-202

P2

Terminated

Gastroesophageal Reflux

2012-05-29

Recent News Events

Date

Type

Title